Preclinical and Clinical Proof-of-Concept Studies of PARP Inhibitors with or without DNA-Damaging Chemotherapeutic Agents for TNBC


Preclinical and Clinical Proof-of-Concept Studies of PARP Inhibitors with or without DNA-Damaging Chemotherapeutic Agents for TNBC
Slides from presentations at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)

Ossovskaya V et al. Cell cycle effects of iniparib, a PARP inhibitor, in combination with gemcitabine and carboplatin in the MDA-MB-468(-) triple-negative breast cancer (TNBC) cell line. San Antonio Breast Cancer Symposium 2010;Abstract P5-06-09.

Moulder S et al. A phase 1b study to assess the safety and tolerability of iniparib (BSI-201) in combination with irinotecan for the treatment of patients with metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2010;Abstract P6-15-01.

Veeck J et al. Promoter CpG methylation of BRCA1 predicts sensitivity to PARP inhibitors in breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S4-8.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.